Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/15/2018 |
| Start Date: | April 2016 |
| End Date: | December 2019 |
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy
This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a
single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK
inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)
single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK
inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)
Inclusion Criteria:
- Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
- Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events
within prior 9 months
- Presence of measurable disease
Exclusion Criteria:
- Progression on prior BTK or PI3K delta inhibitor
- Prior treatment with TGR-1202
- Richter's transformation or CLL transformation to aggressive lymphoma
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials